REDMOND, Wash., Aug. 24, 2026 (GLOBE NEWSWIRE) — Pattern Computer®, Inc. (“Pattern” or “the Company”), the global leader in Pattern Discovery, in collaboration with the Medical College of Wisconsin (MCW), the Froedtert & the Medical College of Wisconsin Clinical Cancer Center on the Froedtert Hospital campus, and the Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine at MCW, today announced the publication of initial results in their groundbreaking research underway on rapid, Point-of-Care (PoC) tier-1 cancer screening using Pattern’s ProSpectral™ device.

The study is led by Razelle Kurzrock, MD, FACP, a world-renowned leader in precision oncology and rare cancers research. Dr. Kurzrock is the Director of the Center for Precision Oncology and Rare Cancers at the MCW Cancer Center, Associate Director of Precision Oncology at the Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, and the founding director of the Michels Rare Cancers Research Laboratories at the MCW Cancer Center. She is recognized by GPS Scholar as number 1 in the precision medicine field worldwide.

Dr. Kurzrock is joined by Hui Zi Chen, MD, PhD, and Ann Maguire, MD, MPH, esteemed MCW colleagues who are co-leading the study at the Froedtert & MCW Clinical Cancer Center. Dr. Maguire leads the study in the Hereditary Cancer Risk Clinic. Dr. Chen is an expert in precision medicine, rare cancers, and lung cancer in the Precision Medicine and Rare Cancers Clinic and leads the study in the Lung Cancer Clinic.

An abstract of the study in progress, which pairs saliva transmission hyperspectral spectroscopy with advanced machine learning, has been published at the annual meeting of the American Society of Clinical Oncology (ASCO), as well as in the Journal of Clinical Oncology. The research team also presented their findings via a poster presentation at the annual meeting of the Association for Diagnostics & Laboratory Medicine (ADLM), which took place July 26 – 30, 2026 in Anaheim, CA.

Solving the Tier-1 Screening Bottleneck
Effective tier-1 cancer screening can benefit from rapid, inexpensive, and highly specific testing to minimize unnecessary downstream workups and anxiety for patients. Current centralized laboratory workflows, such as sequencing-based cfDNA blood assays, typically require a two-week turnaround time and high reagent costs.

By contrast, the newly evaluated method can support sub-minute time-to-results at the point of care, completely avoid reagent costs, and discriminate as well as traditional sequencing-based cfDNA methylation blood assays at a comparable cohort scale.

Study Design and Methodology
The clinical evaluation was conducted under an IRB-approved protocol (PREDICT NCT05802069) using saliva collected from outpatient consented participants at MCW facilities:

  • Cohort Size: 251 total participants, including 99 from a lung cancer clinic and 152 from a high-risk clinic.
  • Rapid Collection: Just two drops of saliva were scanned in approximately 3 seconds using a ProSpectral™ hyperspectral spectrophotometric device to capture transmission spectra.
  • Algorithmic Classification: The data were analyzed using Pattern Computer’s proprietary Pattern Discovery Engine™ (PDE™). PDE models generate human-readable symbolic equations in the spectral domain, providing true explainability, and allowing researchers to calibrate operating thresholds specifically for high-specificity, low false-positive tier-1 operations.

Promising High-Specificity Results
Patient data were categorized into four distinct clinical states: cancer-positive (n = 99), hereditary cancer-predisposition without diagnosis (n = 86), no evidence of disease (NED) while on treatment (n = 16), and NED at least 2 months post-treatment (n = 50).

The predictive models successfully maintained robust discrimination under strict settings designed to eliminate false positives. Initial performance metrics across the 251-sample cohort demonstrated:

  • Specificity: 91%
  • Balanced Accuracy: 61%
  • Sensitivity: 44%
  • F1-Score: 0.55

Statistical saturation analysis indicates that specificity exceeding 98% is likely attainable with a cohort of fewer than 500 samples, establishing a clear path toward a clinically actionable screening protocol.

Next Steps and Ongoing Work
“The ProSpectral data demonstrates that saliva transmission hyperspectral spectroscopy, powered by our Pattern Discovery Engine, establishes a highly scalable, near-real-time paradigm for early cancer screening and triage,” commented Mark R. Anderson, Pattern Chair and CEO. “We are not merely adjusting current diagnostic workflows; we are completely disrupting them. This innovation shifts the diagnostic timeline from weeks to a sub-minute at the point of care, equaling traditional sequencing-based blood assays at scale, while completely removing chemical reagent costs from the equation.”

Anderson concluded, “Ongoing development is focused on attributing specific discriminative spectral signatures to underlying biological markers. The joint team can use orthogonal assays, including fractionation and targeted mass spectrometry, to identify the contributing analytes and host-response biomarkers. This work will further improve the system’s interpretability ahead of upcoming prospective validation trials.”

About Pattern
Pattern Computer®, Inc. is a next-generation AI platform company which uses its Pattern Discovery Engine™ (PDE) to solve the most important and intractable problems in business and medicine. These proprietary mathematical techniques in advanced AI can find complex patterns in very-high-order data that have eluded detection by much larger systems, including LLMs. As the Company applies its PDE to the challenging fields of drug discovery and diagnostics, it has also made major Pattern Discoveries for partners in other sectors, including extended biotech, materials science, aerospace manufacturing quality control, veterinary medicine, equity trading, AI regulatory compliance, energy services and more. www.patterncomputer.com.

About the Medical College of Wisconsin
With a history dating back to 1893, the Medical College of Wisconsin is dedicated to leadership and excellence in education, patient care, research, and community engagement. More than 1,700 students are enrolled in MCW’s medical, graduate and pharmacy schools at campuses in Milwaukee, Green Bay, and Central Wisconsin. MCW’s School of Pharmacy opened in 2017. A major national research center, MCW ranks in the top 4% of U.S. research institutions (InCites Essential Science Indicators Dataset), is the largest research institution in the Milwaukee metro area and is the largest private research institution in Wisconsin. Annually, our faculty direct or collaborate on more than 5,100 research studies, including clinical trials. In the last 10 years, MCW faculty have received nearly $2 billion in external support for research, teaching, training, and related purposes. Additionally, our more than 1,900 physicians provide care in virtually every specialty of medicine, annually fulfilling more than 5.7 million patient visits.

CONTACT: Laura Guerrant-Oiye (808) 960-2642 – laura@patterncomputer.com

The foregoing contains statements about Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws and are based on current information and/or management’s good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.

Copyright © 2026 Pattern Computer Inc. All Rights Reserved. Pattern Computer, Inc., Pattern Discovery Engine, PatternBio, TrueXAI, and ProSpectral are trademarks of Pattern Computer Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.


Primary Logo

About The Author
PATTERN COMPUTER, INC.